Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T18:04:11.374Z.
Calculation as of: 2026-10-06T18:04:11.374Z.
Quote observation: 2026-10-06T18:00:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 48a0ac2e06a305f3cd7951aab0857df1d764d6a3c57040a498ae406f98205111
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
NewAmsterdam Pharma Company N.V.
Market Cap
$2.52B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.57B
EV/FCF Ratio
N/A
TTM Avg
22.38x
3Y Avg
30.75x
5Y Avg
68.64x
Market Cap
$2.59B
EV/FCF Ratio
N/A
TTM Avg
44.45x
3Y Avg
44.45x
5Y Avg
44.45x
Market Cap
$2.43B
EV/FCF Ratio
122.06x
TTM Avg
54.29x
3Y Avg
27.10x
5Y Avg
23.78x
Market Cap
$2.40B
EV/FCF Ratio
29.66x
TTM Avg
35.75x
3Y Avg
35.25x
5Y Avg
31.41x
Market Cap
$2.66B
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.66B
EV/FCF Ratio
25.66x
TTM Avg
31.01x
3Y Avg
94.23x
5Y Avg
120.63x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. (NAMS) | $2.52B | N/A | N/A | N/A | N/A |
| Privia Health Group, Inc. (PRVA)vs › | $2.57B | N/A | 22.38x | 30.75x | 68.64x |
| Beam Therapeutics Inc. (BEAM)vs › | $2.59B | N/A | 44.45x | 44.45x | 44.45x |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.43B | 122.06x | 54.29x | 27.10x | 23.78x |
| Disc Medicine, Inc. (IRON)vs › | $2.42B | N/A | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | 29.66x | 35.75x | 35.25x | 31.41x |
| Neogen Corporation (NEOG)vs › | $2.65B | N/A | 247.54x | 95.89x | 78.72x |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.66B | N/A | N/A | N/A | N/A |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.66B | 25.66x | 31.01x | 94.23x | 120.63x |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.38B | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
